| Abstrak/Abstract |
Diabetic Peripheral Neuropathy (DPN) significantly affects the quality of life with no definitive therapy currently. Given the pathologic basis for DPN treatment, it's critical to promote neuron regeneration while also restricting nerve degeneration. Schwann cells (SC) that play pivotal roles against peripheral regeneration manifest cell proliferation inhibition in diabetic patients accompanied by peripheral regeneration capacity reduction. DLBS1033N, a protein hydrolysate obtained from Lumbricus rubellus, has been confirmed to promote Schwann cell line RSC96 growth and survival by inducting Nerve Growth Factor (NGF) expression via phosphatidylinositol-3 kinase (PI3K) pathway. This pathway has important contribution to SC proliferation and migration during the regeneration process. Herein the contribution of DLBS1033N to peripheral regeneration on high-glucose (50mM)-induced rat Schwann cell line RSC96 injury, a well-known DPN in vitro cell model, was evaluated. RSC96 were treated with high glucose (50mM) with or without DLBS1033N 25, 50, and 100 μg/mL for 24, 48, and 72 h. MTS assay kits were used to evaluate cell viability. DLBS1033N significantly improves cell proliferation in 48 h incubation time in a dose-dependent manner (p < 0.05). Furthermore, DLBS1033N 100 μg/ml significantly increased cell migration by 19% in 48 H incubation (p < 0.05) determined by scratch assay. In conclusion, DLBS1033N enhanced peripheral regeneration which could be used as an effective and promising DPN treatment. |
